“In the short time since early and full approval, the standard-of-care first-line treatment is seeing tremendous progress,” said Precigen’s (PGEN) President and CEO, Helen Sabzevari, during a conference call to discuss fourth quarter results. “This substantial advancement constitutes a pivotal milestone for all stakeholders impacted by RRP.” As a result of the interest in PAPZIMEOS, Sabzevari said the company is transforming from a research and development biopharmaceutical company to a product revenue generating biotech company. Net product sales of PAPZIMEOS were $3.4M in the fourth quarter of 2025, with shipments commencing in November. In the fourth quarter, Precigen patient hub enrollment surpassed 300, a testament to physician and patient demand. Sabzevari noted the company expects revenue in the first quarter of 2026 to exceed $18M given the momentum of PAPZIMEOS. “This is a clear sign of the enthusiasm we are seeing from patients and physicians alike, leading to a robust use of the immunotherapy,” she said.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PGEN:
